Spain ranks first in Europe for clinical trials and is attracting investment in life sciences, but faces intense competition ...

Highlighted with 90 tables and 69 figures, this 168-page report ?Asia Pacific Pharmaceutical Manufacturing Industry 2022-2032 by Formulation, Route of Administration, Consumer Group, Therapeutic ...

Highlighted with 93 tables and 69 figures, this 168-page report ?Europe Pharmaceutical Manufacturing Industry 2022-2032 by Formulation, Route of Administration, Consumer Group, Therapeutic Application ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

US Services’ rilzabrutinib orphan designation as a treatment of immunoglobulin G4-related disease, according to a ...

US biotech AIRNA has raised $155 million in series B funding to advance its lead RNA-editing therapy into human trials and ...

The FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or ...

The FDA approves Sanofi's Qfitlia as the first therapy in the United States to treat hemophilia A or B with or without ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.